In recent years, the consumption of dietary supplements has grown worldwide, particularly in developed regions. However, this growing market has also become a prime target for adulteration practices, with some manufacturers illegally adding pharmaceuticals into plant-based food supplements (PFS) to enhance their effects. While extensive research has focused on detecting adulterant drugs in PFS tailored for improving sexual performance, weight loss, and muscle building, less attention has been given to supplements intended for mood enhancement, sleep aid, and cognitive function (nootropics). Nonetheless, recent reports indicate an increasing level of adulteration within this group of PFS. Therefore, this review aims at providing a comprehensive overview on the adulteration of PFS tailored for brain health, with a focus on the analytical techniques utilized for detection while also presenting data on consumption patterns and the prevalence of reported adulterants. Considering that the detection of such fraudulent practices primarily relies on chromatographic techniques coupled with mass spectrometry (MS), the developments in this field comprising either targeted or untargeted analysis of pharmaceutical adulterants are discussed.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10969376 | PMC |
http://dx.doi.org/10.3390/foods13060908 | DOI Listing |
Neurology
September 2011
Banner Alzheimer's Institute, 901 E Willetta Street, Phoenix, AZ 85006, USA.
Arch Gen Psychiatry
August 2011
Banner Alzheimer's Institute, 901 E Willetta St., Phoenix, AZ 85006, USA.
Arch Neurol
October 2011
Division of Epidemiology, University of California, Berkeley, 94720-3190, USA.
Objective: To delineate the trajectories of Aβ42 level in cerebrospinal fluid (CSF), fludeoxyglucose F18 (FDG) uptake using positron emission tomography, and hippocampal volume using magnetic resonance imaging and their relative associations with cognitive change at different stages in aging and Alzheimer disease (AD).
Design: Cohort study.
Setting: The 59 study sites for the Alzheimer's Disease Neuroimaging Initiative.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!